Results 61 to 70 of about 88,182,083 (298)

Impact of recent methamphetamine use on treatment outcomes among individuals initiating medications for opioid use disorders in rural treatment settings: a 1-year retrospective cohort study

Rural and Remote Health
Introduction: Rates of N-methylamphetamine (methamphetamine) use in rural areas of the US have been steadily increasing, particularly among individuals who are already struggling with opioid use disorder.
Leslie Kenefick, Lisa Khairy, Luke Hall, Kibeom Kwon, Nicole Limberg, Kirsi Kirk-Lewis, Megan Lewis, Matt Owen, Sterling McPherson, Andre Miguel   +9 more
doaj   +1 more source

Inability to contact opioid agonist therapy prescribers during the COVID-19 pandemic in a Canadian setting: a cross-sectional analysis among people on opioid agonist therapy

Addiction Science & Clinical Practice, 2022
Background The COVID-19 pandemic and consequent public health response may have undermined key responses to the protracted drug poisoning crisis, including reduced access to opioid agonist therapy (OAT) among people with opioid use disorder.
Soroush Moallef, Kora DeBeck, Nadia Fairbairn, Zishan Cui, Rupinder Brar, Dean Wilson, Cheyenne Johnson, M.-J. Milloy, Kanna Hayashi   +8 more
doaj   +1 more source

Rapid Access to Medications for Opioid Use Disorder [PDF]

Journal of General Internal Medicine, 2021
Robert A. Kleinman, Nathaniel P. Morris
openaire   +2 more sources

Medication-Assisted Treatment of Adolescents With Opioid Use Disorders [PDF]

Pediatrics, 2016
Opioid use disorder is a leading cause of morbidity and mortality among US youth. Effective treatments, both medications and substance use disorder counseling, are available but underused, and access to developmentally appropriate treatment is severely restricted for adolescents and young adults.
Sheryl A. Ryan, Pamela K. Gonzalez, Stephen W. Patrick, Joanna Quigley, Lorena Siqueira, Leslie R. Walker   +5 more
openaire   +2 more sources

Practice guidelines for the administration of buprenorphine for treating opioid use disorder.

, 2021
The Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder provides eligible US physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, and ...

core  

Age‐Related Lamin B1 Deficiency Activates SLC7A11‐Dependent Disulfidptosis to Impair Osteogenesis via Intercepting Mitochondrial Fission

Advanced Science, EarlyView.
This study reveals that age‐related LMNB1 deficiency in mesenchymal stem cells epigenetically upregulates SLC7A11, triggering actin disulfidptosis and mitochondrial dysfunction. This cascade impairs bone formation in senile osteoporosis. Furthermore, researchers identified the FDA‐approved drug naldemedine as a targeted SLC7A11 inhibitor to reverse ...
Wenhui Yu, Qibo Li, Weihao Zhang, Guan Zheng, Junhua Chen, Yipeng Zeng, Zipeng Xiao, Zibin Chen, Ziqian Liu, Yangfeng Lin, Jiajie Lin, Zepeng Su, Zhongyu Xie   +12 more
wiley   +1 more source

Effective treatments for opioid use disorder: A systematic review [PDF]

, 2018
Opioid use disorder is reaching a crisis point globally with many individuals severely impacted. Evidence illustrates that medication-assisted treatment (MAT) is effective in helping individuals overcome opioid use disorder.
Moore, Jill
core   +1 more source

Examining buprenorphine compared to methadone for likelihood of overdose during pregnancy, 2014–2021

Pregnancy
Objective To examine the likelihood of experiencing an overdose among women receiving any buprenorphine (with or without naloxone) compared to women receiving methadone during pregnancy.
Amy Board, Alana M. Vivolo‐Kantor, Shin Y. Kim, Shawn A. Thomas, Emmy L. Tran, Mishka Terplan, Pilar M. Sanjuan, Marcela C. Smid, Tanner Wright, Neil S. Seligman, Patrick D. Schneider, Autumn Davidson, Michelle L. Henninger, Elisha M. Wachman, Kara M. Rood, Luigi Garcia Saavedra, Judette Louis, Diane Morse, Julie Shakib, Kelley A. Saia, Kathryn Miele   +20 more
doaj   +1 more source

The impact of COVID-19 on the treatment of opioid use disorder in carceral facilities: a cross-sectional study

Health & Justice, 2022
While the COVID-19 pandemic disrupted healthcare delivery everywhere, persons with carceral system involvement and opioid use disorder (OUD) were disproportionately impacted and vulnerable to severe COVID-associated illness.
Elizabeth C. Saunders, Milan F. Satcher, Laura B. Monico, Ryan D. McDonald, Sandra A. Springer, David Farabee, Jan Gryczynski, Amesika Nyaku, Donald Reeves, Lynn E. Kunkel, Alysse M. Schultheis, Robert P. Schwartz, Joshua D. Lee, Lisa A. Marsch, Elizabeth Needham Waddell   +14 more
doaj   +1 more source

The impact of stigma surrounding use of medications for opioid use disorder.

, 2020
Substance use disorders (SUDs) are highly stigmatized conditions, with stigma hindering and discouraging individuals from seeking treatment services. Not only does stigma exist for individuals with SUDs, but also for individuals who use medications to ...

core